Matinicus Pharma
Matinicus Pharma is a life sciences company focused on developing stabilized, ultra-pure bovine hemoglobin solutions for addressing local and systemic oxygen deprivation. The company applies proprietary manufacturing techniques to produce universally compatible, room-temperature stable hemoglobin-based oxygen carriers suitable for clinical emergency, organ transplantation, and veterinary applications. Founded by experts in biologics purification and clinical development, it targets unmet medical needs in human and animal health by providing alternatives to traditional blood transfusion and enhancing organ preservation.
Industries
N/A
Matinicus Pharma
Fitzrovia Hospital, 13-14 Fitzroy Square, London, W1T 6AH
Products
A modified and stabilized bovine hemoglobin protein formulated as an injectable solution designed to deliver oxygen in cases of hypoxia, ischemia, trauma, or during organ preservation.
A modified and stabilized bovine hemoglobin protein formulated as an injectable solution designed to deliver oxygen in cases of hypoxia, ischemia, trauma, or during organ preservation.
Expertise Areas
- Hemoglobin-based oxygen carrier therapeutics
- Biologic drug product development
- Organ transplantation preservation solutions
- Veterinary intravenous therapeutics
Key Technologies
- Hemoglobin-based oxygen carriers
- Ultra-pure protein chromatography
- Single-use modular biomanufacturing
- Liquid and dry protein stabilization
Key People
Founder & Medical Director
Chief Scientific Advisor
Founder & Medical Director
Chief Scientific Advisor
News & Updates
Patent covering the composition and process for stabilized hemoglobin-based oxygen carriers, with strong IP position in composition of matter and process.
Patent covering the composition and process for stabilized hemoglobin-based oxygen carriers, with strong IP position in composition of matter and process.